• Rohini Suryabhan Dongare
• Shraddha Balasaheb Amate
• Tejas Uddhav Amrute

The current Severe Acute Respiratory Distress Syndrome (SARS-CoV-2) coronavirus 2 pandemic poses significant health dangers to patients and professionals all around the world. In the covid- 19 epidemic, the antiviral medicine remdesivir is regarded as a “molecule of hope.” Under the brand name Vecklury, Remdesivir (GS-5734) is the leading certified medication for extreme coronavirus disease 2019 (COVID-19). It’s a one-of-a-kind nucleoside analogue having antiviral properties against Ebola virus (EBOV) and respiratory infections like Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV and SARS-CoV-2. In May 2020, the FDA gave Remdesivir its imprimatur for hospitalized patients. It is the first licensed medicament to be utilized in treatment of the Covid-19. The medicine was initially identified in 2016 and is a derivative of an antiviral library of small compounds designed to prevent the spread of dangerous RNA viruses. Remdesivir reduces the time it takes for hospitalized patients who require auxiliary oxygen to be retrieved and may have an efficacious effect on mortality outcomes while also giving a good protective outline. Remdesivir’s analytical determinations were summarized, including mechanism of action, pharmacokinetics, administration, and adverse effects.

Remdesivir, Covid-19, US FDA, SARS-CoV 2, MERS- CoV, Ebola virus, Nucleoside Analogue

"A Review On:Remdesivir As Effective Drug In Covid-19 Treatment", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.8, Issue 10, page no.b20-b24, October-2021, Available :http://www.jetir.org/papers/JETIR2110103.pdf

"A Review On:Remdesivir As Effective Drug In Covid-19 Treatment", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.8, Issue 10, page no. ppb20-b24, October-2021, Available at : http://www.jetir.org/papers/JETIR2110103.pdf